Literature DB >> 17288921

[Cardiovascular risk profile of uncontrolled hypertensive patients. The Control-Project study].

Emilio Márquez-Contreras1, Antonio Coca, Mariano de la Figuera von Wichmann, Juan Antonio Divisón, José Luis Llisterri, Javier Sobrino, Claudia Filozof, Miguel Angel Sánchez-Zamorano, Lilian Grigorian Shamagian.   

Abstract

BACKGROUND AND
OBJECTIVE: To assess absolute cardiovascular risk and co-morbidities in uncontrolled hypertensive patients (blood pressure [BP]>or=140/90 mmHg or>or=130/80 mmHg in diabetics) attending Primary Care Physicians in Spain, and to determine the attitudes of these physicians towards this problem. PATIENTS AND
METHOD: Cross-sectional, multicenter study involving 356 general practitioners around Spain. Absolute cardiovascular risk was assessed according to ESH-ESC 2003 Guidelines in a sample of 1,710 patients.
RESULTS: Two hundred ninety seven patients were excluded by several reasons and a total of 1,413 hypertensive patients were valuable (mean age: 65.3+/-11.4 years; 56.7% women). Normal BP values (<140/90 mmHg) were exhibited by 0.2%, high-normal BP (120-139/80-89 mmHg) were exhibited by 2.8%, grade 1 hypertension (140-159/90-99 mmHg) by 49.9%, grade 2 hypertension (160-179/100-109 mmHg) by 39.3%, and grade 3 hypertension (>or=180/110 mmHg) by 7.9%. Associated cardiovascular risk factors were observed in 96.0% of patients (95% CI=94.7-97.2%), target organ damage in 34.5% (95% CI=31.6-36.5%), and cardiovascular clinical disease in 36.0% (95% CI=33.5-38.5%). According to ESH-ESC 2003 Guidelines 34.0% (CI=31.5-38.2%) were at very-high risk; 29.4% (95% CI=26.4-32.8%) at high risk; 30.4% (95% CI=27.2-33.7%) at moderate risk and 5.4% (95% CI=3.9-7.2%) at low risk of cardiovascular disease. Despite the high absolute risk, physicians did not do any therapeutic change in 30.4% (95% CI=28.2-33.5%) of uncontrolled hypertensive patients. Most of them (64.26%) considered that bad compliance to life style changes was the reason for inadequate BP control. The most frequent measure introduced was the association of additional drugs.
CONCLUSIONS: Absolute cardiovascular risk in uncontrolled hypertensive patients attending Primary Care Physicians in Spain is very relevant. Sixty-five percent of these patients are at high or very high risk with a high prevalence of target organ damage or associated cardiovascular clinical disease. Therapeutic attitudes towards these patients are still very conservative although they are improving compared with previous studies.

Entities:  

Mesh:

Year:  2007        PMID: 17288921     DOI: 10.1016/s0025-7753(07)72498-3

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  13 in total

1.  Hypertensive emergencies in children.

Authors:  Pankaj Hari; Aditi Sinha
Journal:  Indian J Pediatr       Date:  2011-01-27       Impact factor: 1.967

2.  [Lifestyles of subjects who take drugs for two or more cardiovascular risk factors. TAR-RISC Study].

Authors:  Josep Carles Llop Margalef; Silvia Hernández Anadón; Josep Bítria Ibars; Albert Josa; José María Crespo; Ferran Bejarano Romero; Carles Llor
Journal:  Aten Primaria       Date:  2010-05-20       Impact factor: 1.137

3.  Suitability of antiplatelet therapy in hypertensive patients.

Authors:  M J Martínez-Orozco; Z Perseguer-Torregrosa; V F Gil-Guillén; A Palazón-Bru; D Orozco-Beltran; C Carratalá-Munuera
Journal:  J Hum Hypertens       Date:  2014-04-03       Impact factor: 3.012

4.  Is there a predictive profile for clinical inertia in hypertensive patients? An observational, cross-sectional, multicentre study.

Authors:  Vicente Gil-Guillén; Domingo Orozco-Beltrán; Emilio Márquez-Contreras; Ramón Durazo-Arvizu; Richard Cooper; Salvador Pita-Fernández; Diego González-Segura; Concepción Carratalá-Munuera; José Luis Martín de Pablo; Vicente Pallarés; Salvador Pertusa-Martínez; Antonio Fernández; Josep Redón
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

5.  [Objective KONTROL study: therapeutic inertia in hypertensive patients attended in primary care of Spain].

Authors:  Carlos Sanchis Doménech; José Luis Llisterri Caro; Vicente Palomo Sanz; Francisco Javier Alonso Moreno; Isidro López Rodríguez; Armando Nevado Loro; Miguel Ángel Zamorano; Natividad Gil García; M Dolores Aguilar Conesa; Pablo Lázaro Y de Mercado
Journal:  Aten Primaria       Date:  2011-03-17       Impact factor: 1.137

6.  [Control of therapeutic inertia in the treatment of arterial hypertension by using different strategies].

Authors:  Emilio Márquez Contreras; Nieves Martel Claros; Vicente Gil Guillén; José Luis Martín De Pablos; Mariano De La Figuera Von Wichman; José Joaquin Casado Martínez; Jacinto Espinosa García
Journal:  Aten Primaria       Date:  2009-05-31       Impact factor: 1.137

7.  EDUCORE project: a clinical trial, randomised by clusters, to assess the effect of a visual learning method on blood pressure control in the primary healthcare setting.

Authors:  Isidro Rodríguez-Salceda; Esperanza Escortell-Mayor; Milagros Rico-Blázquez; Rosario Riesgo-Fuertes; Angel Asúnsolo-del Barco; Antonio Valdivia-Pérez; Isabel del Cura-González; Ana B García-Cañón; María F Ortiz-Jiménez; Luisa Cabello-Ballesteros; Sofia Garrido-Elustondo; Laura Chamorro-González; Ricardo Rodríguez-Barrientos
Journal:  BMC Public Health       Date:  2010-07-30       Impact factor: 3.295

8.  Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2010-05-10

9.  The epidemiology and management of severe hypertension.

Authors:  A M Borzecki; B Kader; D R Berlowitz
Journal:  J Hum Hypertens       Date:  2010-01       Impact factor: 3.012

10.  A quality improvement plan for hypertension control: the INCOTECA Project (INterventions for COntrol of hyperTEnsion in CAtalonia).

Authors:  Roser Vallès-Fernandez; Magdalena Rosell-Murphy; Olga Correcher-Aventin; Lucas Mengual-Martínez; Núria Aznar-Martínez; Gemma Prieto-De Lamo; Alícia Franzi-Sisó; Jordi Puig-Manresa; Josep Ma Bonet-Simó
Journal:  BMC Public Health       Date:  2009-03-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.